Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 171

1.

Prognostic Significance of Hyponatremia in Acute Intracerebral Hemorrhage: Pooled Analysis of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial Studies.

Carcel C, Sato S, Zheng D, Heeley E, Arima H, Yang J, Wu G, Chen G, Zhang S, Delcourt C, Lavados P, Robinson T, Lindley RI, Wang X, Chalmers J, Anderson CS; Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial 2 Investigators.

Crit Care Med. 2016 Jul;44(7):1388-1394.

PMID:
26958746
2.

Estimated GFR and the Effect of Intensive Blood Pressure Lowering After Acute Intracerebral Hemorrhage.

Zheng D, Sato S, Arima H, Heeley E, Delcourt C, Cao Y, Chalmers J, Anderson CS; INTERACT2 Investigators.

Am J Kidney Dis. 2016 Jul;68(1):94-102. doi: 10.1053/j.ajkd.2016.01.020. Epub 2016 Mar 3.

3.

Outcomes of Two Trials of Oxygen-Saturation Targets in Preterm Infants.

BOOST-II Australia and United Kingdom Collaborative Groups, Tarnow-Mordi W, Stenson B, Kirby A, Juszczak E, Donoghoe M, Deshpande S, Morley C, King A, Doyle LW, Fleck BW, Davis PG, Halliday HL, Hague W, Cairns P, Darlow BA, Fielder AR, Gebski V, Marlow N, Simmer K, Tin W, Ghadge A, Williams C, Keech A, Wardle SP, Kecskes Z, Kluckow M, Gole G, Evans N, Malcolm G, Luig M, Wright I, Stack J, Tan K, Pritchard M, Gray PH, Morris S, Headley B, Dargaville P, Simes RJ, Brocklehurst P.

N Engl J Med. 2016 Feb 25;374(8):749-60. doi: 10.1056/NEJMoa1514212. Epub 2016 Feb 10.

PMID:
26863265
4.

Low Ambient Temperature and Intracerebral Hemorrhage: The INTERACT2 Study.

Zheng D, Arima H, Sato S, Gasparrini A, Heeley E, Delcourt C, Lo S, Huang Y, Wang J, Stapf C, Robinson T, Lavados P, Chalmers J, Anderson CS; INTERACT2 investigators.

PLoS One. 2016 Feb 9;11(2):e0149040. doi: 10.1371/journal.pone.0149040. eCollection 2016.

5.

Determinants and Prognostic Significance of Hematoma Sedimentation Levels in Acute Intracerebral Hemorrhage.

Sato S, Delcourt C, Zhang S, Arima H, Heeley E, Zheng D, Al-Shahi Salman R, Stapf C, Tzourio C, Robinson T, Lindley RI, Chalmers J, Anderson CS; INTERACT2 Investigators.

Cerebrovasc Dis. 2016;41(1-2):80-6. doi: 10.1159/000442532. Epub 2015 Dec 16.

PMID:
26671408
6.

Off-Hour Admission and Outcomes in Patients with Acute Intracerebral Hemorrhage in the INTERACT2 Trial.

Sato S, Arima H, Heeley E, Hirakawa Y, Delcourt C, Lindley RI, Robinson T, Huang Y, Morgenstern L, Stapf C, Wang J, Chalmers J, Anderson CS; INTERACT2 Investigators.

Cerebrovasc Dis. 2015;40(3-4):114-20. doi: 10.1159/000434690. Epub 2015 Jul 18.

PMID:
26202097
7.

Australian clinical trial activity and burden of disease: an analysis of registered trials in National Health Priority Areas.

Lam J, Lord SJ, Hunter KE, Simes RJ, Vu T, Askie LM.

Med J Aust. 2015 Jul 20;203(2):97-101.

PMID:
26175250
8.

Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer.

Schofield PE, Stockler MR, Zannino D, Tebbutt NC, Price TJ, Simes RJ, Wong N, Pavlakis N, Ransom D, Moylan E, Underhill C, Wyld D, Burns I, Ward R, Wilcken N, Jefford M.

Support Care Cancer. 2016 Jan;24(1):401-8. doi: 10.1007/s00520-015-2792-8. Epub 2015 Jun 21.

PMID:
26093975
9.

Higher mortality in patients with right hemispheric intracerebral haemorrhage: INTERACT1 and 2.

Sato S, Heeley E, Arima H, Delcourt C, Hirakawa Y, Pamidimukkala V, Li Z, Tao Q, Xu Y, Hennerici MG, Robinson T, Tzourio C, Lindley RI, Chalmers J, Anderson CS; INTERACT Investigators, Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, Heeley E, Skulina C, Parsons MW, Kim JS, Tao QL, Li YC, Jiang JD, Tai LW, Zhang LJ, Xu E, Cheng Y, Heritier S, Morgenstern LB, Chalmers J.

J Neurol Neurosurg Psychiatry. 2015 Dec;86(12):1319-23. doi: 10.1136/jnnp-2014-309870. Epub 2015 Jan 14.

PMID:
25589782
10.

Optimal achieved blood pressure in acute intracerebral hemorrhage: INTERACT2.

Arima H, Heeley E, Delcourt C, Hirakawa Y, Wang X, Woodward M, Robinson T, Stapf C, Parsons M, Lavados PM, Huang Y, Wang J, Chalmers J, Anderson CS; INTERACT2 Investigators; INTERACT2 Investigators.

Neurology. 2015 Feb 3;84(5):464-71. doi: 10.1212/WNL.0000000000001205. Epub 2014 Dec 31.

11.

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.

Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF; IBIS-I Investigators.

Lancet Oncol. 2015 Jan;16(1):67-75. doi: 10.1016/S1470-2045(14)71171-4. Epub 2014 Dec 11.

12.

Sentinel lymph node based management or routine axillary clearance? Three-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial.

Wetzig N, Gill PG, Zannino D, Stockler MR, Gebski V, Ung O, Campbell I, Simes RJ.

Ann Surg Oncol. 2015 Jan;22(1):17-23. doi: 10.1245/s10434-014-3928-7. Epub 2014 Oct 15.

PMID:
25316485
13.

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.

Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ.

J Am Coll Cardiol. 2014 Aug 5;64(5):485-94. doi: 10.1016/j.jacc.2014.02.615. Review.

14.

Which lipid measurement should we monitor? An analysis of the LIPID study.

Glasziou PP, Irwig L, Kirby AC, Tonkin AM, Simes RJ.

BMJ Open. 2014 Feb 21;4(2):e003512. doi: 10.1136/bmjopen-2013-003512.

15.

Semiparametric methods for multistate survival models in randomised trials.

Hudson HM, Lô SN, Simes RJ, Tonkin AM, Heritier S.

Stat Med. 2014 May 10;33(10):1621-45. doi: 10.1002/sim.6060. Epub 2013 Dec 13.

PMID:
24338893
16.

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.

Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, Malone DP, Langer C, Tebbutt N, Price TJ, Shapiro J, Siu LL, Wong RP, Bjarnason G, Moore MJ, Zalcberg JR, Khambata-Ford S.

Br J Cancer. 2014 Feb 4;110(3):648-55. doi: 10.1038/bjc.2013.753. Epub 2013 Dec 12.

17.

Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.

Ransom D, Wilson K, Fournier M, Simes RJ, Gebski V, Yip D, Tebbutt N, Karapetis CS, Ferry D, Gordon S, Price TJ.

Ann Oncol. 2014 Jan;25(1):117-21. doi: 10.1093/annonc/mdt479. Epub 2013 Dec 2.

18.

Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone.

Lee CK, Gebski VJ, Coates AS, Veillard AS, Harvey V, Tattersall MH, Byrne MJ, Brigham B, Forbes J, Simes RJ; Australia and New Zealand Breast Cancer Trials Group (ANZBCTG).

Springerplus. 2013 Aug 21;2:391. doi: 10.1186/2193-1801-2-391. eCollection 2013.

19.

Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.

Price TJ, Hardingham JE, Lee CK, Townsend AR, Wrin JW, Wilson K, Weickhardt A, Simes RJ, Murone C, Tebbutt NC.

Cancer Med. 2013 Jun;2(3):277-85. doi: 10.1002/cam4.75. Epub 2013 Mar 25.

20.

A funding model for public-good clinical trials.

Winship IM, McNeil J, Simes RJ.

Med J Aust. 2013 Jul 22;199(2):90-1. No abstract available.

PMID:
23879491
Items per page

Supplemental Content

Loading ...
Write to the Help Desk